The MAGED2 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed for targeted disruption of the MAGED2 gene in a human B lymphocyte background. This product provides a heterogeneous pool of Raji cells carrying MAGED2 gene disruptions, enabling loss-of-function studies without clonal selection. The polyclonal format is particularly suited for experiments where population-level responses are informative, such as signaling pathway analyses and apoptosis assays.
The parental Raji cell line is an EBV-positive B lymphocyte line derived from a Burkitt lymphoma patient. Raji cells serve as a well-established model for studying B cell receptor (BCR) signaling, apoptosis mechanisms, and Epstein-Barr virus (EBV) biology. Their transformed phenotype and active signaling networks make them valuable for dissecting oncogenic pathways and lymphomagenesis. The EBV-immortalized nature also provides a context for investigating viral-host interactions and apoptotic resistance in B cell malignancies.
MAGED2, a melanoma-associated antigen D2, is a member of the MAGE family of proteins, implicated in cell cycle regulation, apoptosis, and G protein-coupled receptor (GPCR) signaling modulation. Mechanistically, MAGED2 interacts with G protein alpha subunits G??s (encoded by GNAS) and G??q (encoded by GNAQ) to influence cAMP and calcium second messenger pathways. It also binds the E3 ubiquitin ligase TRIM27, regulating NF-??B activation and apoptosis. Upstream regulators include p53 and DNA methylation, positioning MAGED2 at a nexus of stress responses and proliferative signals. Mutations in MAGED2 cause Bartter syndrome type 5, highlighting its critical role in renal electrolyte transport.
In the Raji B-cell context, disruption of MAGED2 allows researchers to dissect its contributions to GPCR-mediated signaling that may intersect with BCR pathways and lymphoma cell survival. Given the importance of NF-??B for B-cell proliferation and EBV latency, this knockout provides a tool to examine how MAGED2 modulates the TRIM27-NF-??B axis and apoptotic thresholds. Additionally, the model can be used to explore MAGED2-dependent cAMP and calcium dynamics in a lymphoma background, offering insights into signal integration in malignant B cells.
Typical applications include quantitative measurement of cAMP accumulation and calcium mobilization to assess GPCR signaling, NF-??B reporter assays to evaluate transcriptional activity, and flow cytometry-based apoptosis and proliferation studies. Co-immunoprecipitation experiments can confirm molecular interactions with GNAS, GNAQ, and TRIM27, while RT-qPCR and Western blotting enable validation of gene and protein expression changes. The polyclonal population is also suitable for functional screens and Bartter syndrome-relevant electrolyte transport studies in non-polarized cells. For detailed protocols or assistance, please contact Ascent Research.
